Vivozon Healthcare Inc (082800) - Net Assets

Latest as of June 2026: ₩95.30 Billion KRW ≈ $64.59 Million USD

Based on the latest financial reports, Vivozon Healthcare Inc (082800) has net assets worth ₩95.30 Billion KRW (≈ $64.59 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩163.53 Billion ≈ $110.82 Million USD) and total liabilities (₩68.23 Billion ≈ $46.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Vivozon Healthcare Inc to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩95.30 Billion
% of Total Assets 58.28%
Annual Growth Rate 2.46%
5-Year Change -14.63%
10-Year Change 219.51%
Growth Volatility 91.68

Vivozon Healthcare Inc - Net Assets Trend (2009–2025)

This chart illustrates how Vivozon Healthcare Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Vivozon Healthcare Inc market cap and net worth.

Annual Net Assets for Vivozon Healthcare Inc (2009–2025)

The table below shows the annual net assets of Vivozon Healthcare Inc from 2009 to 2025. Also explore 082800 net assets growth trend to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 ₩72.66 Billion
≈ $49.24 Million
-31.72%
2024-12-31 ₩106.43 Billion
≈ $72.12 Million
+2.27%
2023-12-31 ₩104.07 Billion
≈ $70.52 Million
-1.67%
2022-12-31 ₩105.84 Billion
≈ $71.72 Million
+24.34%
2021-12-31 ₩85.12 Billion
≈ $57.68 Million
-21.04%
2020-12-31 ₩107.80 Billion
≈ $73.06 Million
-1.10%
2019-12-31 ₩109.00 Billion
≈ $73.87 Million
+59.24%
2018-12-31 ₩68.45 Billion
≈ $46.38 Million
+325.14%
2017-12-31 ₩16.10 Billion
≈ $10.91 Million
-29.21%
2016-12-31 ₩22.74 Billion
≈ $15.41 Million
-7.75%
2015-12-31 ₩24.65 Billion
≈ $16.71 Million
-27.27%
2014-12-31 ₩33.90 Billion
≈ $22.97 Million
-39.63%
2010-12-31 ₩56.15 Billion
≈ $38.05 Million
+14.05%
2009-12-31 ₩49.23 Billion
≈ $33.37 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Vivozon Healthcare Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 111108.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components ₩376.46 Billion 518.07%
Total Equity ₩72.66 Billion 100.00%

Vivozon Healthcare Inc Competitors by Market Cap

The table below lists competitors of Vivozon Healthcare Inc ranked by their market capitalization.

Company Market Cap
Shinhan Seobu T&D REIT Co Ltd
KO:404990
$148.15 Million
Fong Chien Construction Co Ltd
TWO:5523
$148.21 Million
Amber International Holding Limited
NYSE:AMBR
$148.25 Million
LG Household & Healthcare Ltd Pref
KO:051905
$148.31 Million
Mayur Resources Ltd
AU:MRL
$148.04 Million
Indigo Acquisition Corp. Ordinary Shares
NASDAQ:INAC
$147.99 Million
Dana Brata Luhur PT
JK:TEBE
$147.96 Million
LBS Bina Group Bhd
KLSE:5789
$147.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vivozon Healthcare Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 106,426,761,450 to 72,664,636,240, a change of -33,762,125,210 (-31.7%).
  • Net loss of 32,424,112,960 reduced equity.
  • Other factors decreased equity by 1,338,012,250.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₩-32.42 Billion -44.62%
Other Changes ₩-1.34 Billion -1.84%
Total Change ₩- -31.72%

Book Value vs Market Value Analysis

This analysis compares Vivozon Healthcare Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.11x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 4.90x to 2.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩599.47 ₩2935.00 x
2017-12-31 ₩424.37 ₩2935.00 x
2018-12-31 ₩919.23 ₩2935.00 x
2019-12-31 ₩905.06 ₩2935.00 x
2020-12-31 ₩766.46 ₩2935.00 x
2021-12-31 ₩2504.91 ₩2935.00 x
2022-12-31 ₩2261.07 ₩2935.00 x
2023-12-31 ₩2158.54 ₩2935.00 x
2024-12-31 ₩2026.75 ₩2935.00 x
2025-12-31 ₩1391.90 ₩2935.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vivozon Healthcare Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -44.62%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -54.64%
  • • Asset Turnover: 0.36x
  • • Equity Multiplier: 2.28x
  • Recent ROE (-44.62%) is below the historical average (-28.97%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -3.83% -1.08% 2.24x 1.58x ₩-4.69 Billion
2015 -39.34% -10.81% 1.84x 1.98x ₩-12.16 Billion
2016 -7.83% -2.61% 1.63x 1.85x ₩-4.06 Billion
2017 -41.42% -10.93% 1.68x 2.26x ₩-8.28 Billion
2018 -12.47% -18.55% 0.46x 1.47x ₩-15.38 Billion
2019 -25.69% -62.28% 0.27x 1.51x ₩-38.90 Billion
2020 -40.59% -100.37% 0.18x 2.30x ₩-54.53 Billion
2021 -81.60% -120.31% 0.30x 2.28x ₩-77.97 Billion
2022 -37.70% -77.39% 0.28x 1.77x ₩-50.49 Billion
2023 -3.23% -4.71% 0.41x 1.67x ₩-13.76 Billion
2024 -9.38% -11.39% 0.47x 1.73x ₩-20.62 Billion
2025 -44.62% -54.64% 0.36x 2.28x ₩-39.69 Billion

Industry Comparison

This section compares Vivozon Healthcare Inc's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $82,023,650,620
  • Average return on equity (ROE) among peers: -5.80%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Vivozon Healthcare Inc (082800) ₩95.30 Billion -3.83% 0.72x $148.10 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $2.37 Billion
DongKoo Bio & Pharma Co. Ltd. (006620) $105.33 Billion 1.93% 1.32x $22.84 Million
NatureCell Co.Ltd (007390) $62.68 Billion -30.10% 0.37x $884.84 Million
Sam-A Pharm. Co. Ltd (009300) $79.92 Billion 4.39% 0.39x $57.91 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $226.71 Billion 8.88% 0.27x $80.33 Million
WooGene B&G Co. Ltd (018620) $18.56 Billion 6.88% 0.41x $47.07 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $713.20 Million
EstechPharma Co. Ltd (041910) $89.25 Billion 7.38% 0.10x $43.30 Million
Komipharm International Co. Ltd (041960) $65.54 Billion 20.01% 0.87x $370.23 Million
Eagle Veterinary Technology Co.Ltd (044960) $29.11 Billion 3.53% 0.43x $26.69 Million

About Vivozon Healthcare Inc

KQ:082800 Korea Pharmaceuticals
Market Cap
$148.10 Million
₩218.54 Billion KRW
Market Cap Rank
#17793 Global
#746 in Korea
Share Price
₩2935.00
Change (1 day)
+2.09%
52-Week Range
₩2155.00 - ₩7120.00
All Time High
₩16500.00
About

Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as w… Read more